<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146255">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01854086</url>
  </required_header>
  <id_info>
    <org_study_id>MMC130009-13CTIL</org_study_id>
    <nct_id>NCT01854086</nct_id>
  </id_info>
  <brief_title>Compliance and Persistence With Osteoporosis Treatment and Attitude Towards Future Therapy Among Post-menopausal Israeli Women During Drug Treatment or Drug Holiday</brief_title>
  <acronym>CONTINUITY</acronym>
  <official_title>Compliance and Persistence With Osteoporosis Treatment and Attitude Towards Future Therapy Among Post-menopausal Israeli Women During Drug Treatment or Drug Holiday: Data From a Single Outpatient Endocrine Clinic.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meir Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meir Medical Center</source>
  <oversight_info>
    <authority>Israel: Clalit Health Services</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to provide information about the rate of response and
      persistence to drug therapies for osteoporosis. Another issue examined in this study refers
      to the preferences and concerns about future treatments in patients during &quot;drug holiday&quot;.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Compliance and persistence to osteoporosis drug therapy</measure>
    <time_frame>Participants will be followed for the duration of their clinic visit, an average of 5 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Data collection will be done by questionnaires and from the medical record of the patient. The information collected will include: demographic information, measurements of bone density, additional information about the disease and treatment that the patient receives,prescription purchases and additional drugs the patient is taking (steroids, PPI's(Proton Pump Inhibitors) / H2 receptor antagonists and NSAIDs(Non Steroidal Anti Inflammatories)).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Postmenopausal women</arm_group_label>
    <description>Postmenopausal women treated with bisphosphonates</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaires about compliance and persistence  with bisphosphonates treatment</intervention_name>
    <arm_group_label>Postmenopausal women</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with osteoporosis,who been treated in Endocrinology Clinic of Medical Center
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women

          -  Diagnosis of osteoporosis in the medical record

          -  At least one prescription drug to treat osteoporosis in the last 5 years

          -  Insured by &quot;Clalit&quot; Health Services

          -  Hebrew-speaking capability and readiness to answer a questionnaire

        Exclusion Criteria:

          -  Premenopausal women

          -  No diagnosis of osteoporosis in the medical record

          -  No treatment for osteoporosis in the last 5 years

          -  Women who do not speak Hebrew or are unable to answer a questionnaire
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pnina Rotman, M.D</last_name>
    <phone>972-57-7482609</phone>
    <email>Pnina.Rotman@clalit.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Meir medical center the clalit health care services group</name>
      <address>
        <city>Kfar Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pnina Rotman, M.D</last_name>
      <phone>972-57-7482609</phone>
      <email>Pnina.Rotman@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Pnina Rotman, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <results_reference>
    <citation>Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005 Sep;21(9):1453-60.</citation>
    <PMID>16197664</PMID>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 12, 2013</lastchanged_date>
  <firstreceived_date>May 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <keyword>postmenopausal</keyword>
  <keyword>patient compliance</keyword>
  <keyword>compliance</keyword>
  <keyword>diphosphonates</keyword>
  <keyword>bisphosphonates</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
